Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Body and Mind's Days Payable or its related term are showing as below:
XCNQ:BAMM's Days Payable is not ranked *
in the Drug Manufacturers industry.
Industry Median: 89.79 * Ranked among companies with meaningful Days Payable only.
Body and Mind's Days Payable
declined
from Apr. 2023 (132.55) to Apr. 2024 (115.85).
It may suggest that Body and Mindaccelerated paying its suppliers.
The historical data trend for Body and Mind's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XCNQ:BAMM vs AKAN, OWPC, PTPI: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Body and Mind's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Body and Mind Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Body and Mind's Days Payable distribution charts can be found below:
* The bar in red indicates where Body and Mind's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Body and Mind's Days Payable for the fiscal year that ended in Jul. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Body and Mind (XCNQ:BAMM) has a Days Payable of 115.85 as of Apr. 2024. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Body and Mind and its competitors.
Is Body and Mind's Days Payable too high?
Body and Mind's current Days Payable is 115.85. The Drug Manufacturers industry median Days Payable is 89.79. Body and Mind's value of 115.85 is 29% above this industry median. Overall, Body and Mind has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Body and Mind's Days Payable compare to AKAN and OWPC?
Body and Mind's Days Payable of 115.85 can be compared against companies in the Drug Manufacturers industry. The industry median Days Payable is 89.79. Body and Mind's value of 115.85 is 29% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 89.79, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Body and Mind's current Days Payable of 115.85 is 29% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Body and Mind and its competitors. For the Drug Manufacturers industry, the median Days Payable is 89.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Body and Mind's current Days Payable is 115.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Body and Mind stock overvalued right now?
Body and Mind (XCNQ:BAMM) has a current Days Payable of 115.85. The current Days Payable is 115.85 and 29% above the Drug Manufacturers industry median of 89.79. Body and Mind's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Body and Mind (XCNQ:BAMM), the current Days Payable is 115.85 as of Apr. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Body and Mind Inc is a multi-state cannabis operator, which has retail, distribution, cultivation, and/or processing operations in Nevada, California, Arkansas, Ohio and Illinois. It has developed the marquis lifestyle Body and Mind brand in Nevada with penetration into dispensaries and has expanded its brand and products to dispensaries in California. The Body and Mind brand appeals to a wide range of cannabis consumers with products including flowers, oils, extracts (wax, live resin, ambrosia), and edibles. The Company Operates in Three segments; Wholesale, Retail, and All others. The Majority of revenue is derived from the Retail segment.
14GF Score
Get the complete analysis for XCNQ:BAMM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:BAMM has been successfully added to your 
